Investor Presentaiton
31
MEDI0457 for HPV-Associated Head & Neck Cancer in Phase
1b/2a in Partnership with AstraZeneca
TRIAL: MEDI0457 (VGX-3100 + IL-12) AstraZeneca >>
Phase 1b/2a open label study for
metastatic HPV+ HNSCC with
persistent or recurrent disease
after chemotherapy treatment
Combination with
AstraZeneca's PD-L1
checkpoint inhibitor
(durvalumab)
Primary Endpoints:
Safety, tolerability
Secondary Endpoints:
Immunogenicity, ORR, PFS,
Disease CR, OS
ENROLL
x35
Completed enrollment of 35
subjects in August 2019
TUMOR CORE BIOPSY AT SCREEN & WEEK 10
ā
Planned Dosing Schedule: durvalumab at Weeks 4, 8 and 12
and then every 4 weeks until disease progression, unacceptable
toxicity or withdrawal of consent
1.
3
3.
5.
7.
10.
12.
16.
20.
Planned Dosing Schedule: MEDI0457: Weeks 1, 3, 7 and 12
and then every 8 weeks until disease progression, unacceptable
toxicity or withdrawal of consent
INOVIO
POWERING DNA MEDICINESView entire presentation